Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie McGauran

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of European CME|December 6, 2021
Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient InformationNatalie McGauran, Beate Wieseler
Chest|May 6, 2010
Reporting a systematic reviewBeate Wieseler, Natalie McGauran
BMJ Evidence-Based Medicine|December 11, 2020
From publication bias to lost in information: why we need a central public portal for clinical trial dataBeate Wieseler, Natalie McGauran
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 2, 2017
Secrecy or transparency? The future of regulatory trial dataBeate Wieseler, Natalie McGauran
Hypertension (Dallas, Tex. : 1979)|June 1, 2006
Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?Peter T Sawicki, Natalie McGauran
Journal of Clinical Epidemiology|April 8, 2026
When prices soar, progress stalls: How high drug costs hinder meaningful and ethical medical researchPhilip Kranz, Natalie McGauran, Beate Wieseler
BMJ (Clinical Research Ed.)|July 12, 2019
New drugs: where did we go wrong and what can we do better?Beate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)|November 28, 2012
We need access to data on all clinical trials, not just someBeate Wieseler, Natalie McGauran, Thomas Kaiser
JAMA Internal Medicine|November 4, 2014
New EMA policy-further measures needed to support comparative effectiveness assessmentsBeate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)|October 14, 2010
Finding studies on reboxetine: a tale of hide and seekBeate Wieseler, Natalie McGauran, Thomas Kaiser
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of European CME|December 6, 2021
Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient InformationNatalie McGauran, Beate Wieseler
Chest|May 6, 2010
Reporting a systematic reviewBeate Wieseler, Natalie McGauran
BMJ Evidence-Based Medicine|December 11, 2020
From publication bias to lost in information: why we need a central public portal for clinical trial dataBeate Wieseler, Natalie McGauran
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 2, 2017
Secrecy or transparency? The future of regulatory trial dataBeate Wieseler, Natalie McGauran
Hypertension (Dallas, Tex. : 1979)|June 1, 2006
Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?Peter T Sawicki, Natalie McGauran
Journal of Clinical Epidemiology|April 8, 2026
When prices soar, progress stalls: How high drug costs hinder meaningful and ethical medical researchPhilip Kranz, Natalie McGauran, Beate Wieseler
BMJ (Clinical Research Ed.)|July 12, 2019
New drugs: where did we go wrong and what can we do better?Beate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)|November 28, 2012
We need access to data on all clinical trials, not just someBeate Wieseler, Natalie McGauran, Thomas Kaiser
JAMA Internal Medicine|November 4, 2014
New EMA policy-further measures needed to support comparative effectiveness assessmentsBeate Wieseler, Natalie McGauran, Thomas Kaiser
BMJ (Clinical Research Ed.)|October 14, 2010
Finding studies on reboxetine: a tale of hide and seekBeate Wieseler, Natalie McGauran, Thomas Kaiser
Pageof 3